secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001558370-25-007487
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q1 2025 net loss $15.4M; cash runway into Q1 2027; first FTD-GRN patient dosed at Dose 2
--------------------------------------------------------------------------------

- Net loss of $15.4M ($0.25 per share) vs $16.7M ($0.30 per share) in Q1 2024.
- Cash, cash equivalents and marketable securities $63.4M as of Mar 31, 2025; funding expected into Q1 2027.
- First FTD-GRN patient dosed with Dose 2 PBFT02; second patient enrolled; additional patients being evaluated.
- Enrollment opened for FTD-C9orf72 patients in the upliFT-D study, targeting up to five symptomatic patients.
- R&D expenses decreased to $7.7M from $11.5M; G&A expenses were $6.1M vs $6.5M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025007487/0001558370-25-007487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025007487/pasg-20250513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer